Asia Pacific Transdermal Drug Delivery System Market Key Players and Opportunities by 2027

The Asia Pacific transdermal drug delivery system market is expected to reach US$ 1,736.02 million by 2027 from US$ 1,199.69 million in 2019. The market is estimated to grow at a CAGR of 4.9% from 2020 to 2027.

The Asia Pacific transdermal drug delivery system market is expected to witness significant growth during the forecast period. The growth of the market is expected to be fastest in countries such as China, India, and Australia. The growth of the market in these countries is expected to be fastest due to growing technology, growing geriatric population, increasing prevalence of cardiovascular diseases, and growing demand for non-invasive medical devices. China is the largest market for transdermal drug delivery systems market. The growth of the transdermal drug delivery system market is primarily attributed to the growing technology in China and increasing developments by the market players. The excessive population in China, coupled with the rising prevalence of chronic diseases is offering immense growth opportunities in the transdermal patches and semisolid products for the pain management market. However, considering the geographic and economic operations between Asian countries and China, the countries are expected to witness challenge of COVID-19. The outbreak of disease has badly affected supply chain, and led to shortage of healthcare supplies in the region. Moreover, domestic start-ups backed by international funding have already started witnessing back out from investors putting the development of the products in jeopardy.

Asia Pacific Transdermal Drug Delivery System Market Revenue and Forecast to 2027 (US$ Million)

Asia Pacific Transdermal Drug Delivery System Market Segmentation

By Type

• Transdermal Patches
  • Matrix Patches
  • Microneedle Patches
  • Drug-In-Adhesive Patches
  • Reservoir Membrane Patches
• Transdermal Semisolids
  • Sprays
  • Gels
  • Ointments

By Application

•   

•     Central Nervous System Disorders

•     Pain Management

•     Hormonal Applications

• • Transdermal Estrogen Therapy
  • Testosterone Replacement Therapy

•     Other Applications

By End User

•   

•     Home Care Settings

•     Other End Users

By Country

• China
• India
• Japan
• South Korea
• Australia
• Rest of Asia Pacific

Company Profiles

• Novartis AG
• Luye Pharma Group
• Mylan N.V.
• GlaxoSmithKline plc
• Hisamitsu Pharmaceutical Co., Inc

Asia Pacific Transdermal Drug Delivery System Report Scope